







Disclaimer

- This presentation contains certain forward-looking statements concerning Danone. In some cases, you can identify these forward-looking statements by forward-looking words, such as "estimate", "expect", "anticipate", "project", "plan", "intend", "objective", "believe", "forecast", "guidance", "outlook", "foresee", "likely", "may", "should", "goal", "target", "might", "will", "could", "predict", "continue", "convinced" and "confident," the negative or plural of these words and other comparable terminology. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.
- Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to
 numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forwardlooking statements. For a description of these risks and uncertainties, please refer to the "Risk Factor" section of Danone's Universal
 Registration Document (the current version of which is available on www.danone.com).
- Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.
- All references in this presentation to Like-for-like (LFL) changes, recurring operating income, recurring operating margin, recurring net income, recurring income tax, recurring EPS and free cash flow correspond to financial indicators not defined in IFRS. Please refer to the press release issued on July 29, 2021 for further details on IAS29 (Financial reporting in hyperinflationary economies), the definitions and reconciliation with financial statements of financial indicators not defined in IFRS. Finally, the calculation of ROIC and Net Debt/Ebitda is detailed in the annual registration document.
- Due to rounding, the sum of values presented in this presentation may differ from totals as reported. Such differences are not material.








H1 2021

Highlights



Interim co-CEOs



H1 2021 highlights

A semester of recovery and progress

Back to LFL sales growth

+6.6%

Q2 LFL sales growth

+1.6%

H1 LFL sales growth

Recurring operating margin

13.1%

in a context of negative category mix and accelerated inflation Further progress on portfolio pruning







All categories back to growth in Q2

Q2 like-for-like growth



+4.8%

Continued growth in Dairy driven by Protein and Probiotics 6th consecutive quarter of double-digit growth for Plant-based



+2.8%

High single-digit growth in Adult Nutrition Infant Nutrition back to growth on softer comps and despite category dynamics



+19.5%

Acceleration of the recovery mainly driven by Europe mobility and strong share gains while Emerging geographies are still more impacted by Covid-related restrictions

Driving growth with clear priorities On core portfolio, execution and brand support

Core portfolio renovation & innovation

Strategic channels focus & execution step-up

Targetted brand reinvestment

Driving growth with clear priorities

On core portfolio, execution and brand support

Core portfolio renovation & innovation







Protein Science based reno & inno

Core renovation

Probiotics

Journey extension

Adjacent innovation

Plantbased Adult nutrition

New models

Strategic channels focus & execution step-up



eCommerce acceleration



Away from home recovery



Stepped up RGM and execution focus

Targetted brand reinvestment







Driving growth through renovation and innovation On core portfolio and beyond – H1 highlights







Innovation, renovation & journey extension in Infant Nutrition









Driving growth through renovation and innovation On core portfolio and beyond – Selected H2 plans







Driving growth in key channels

Continued strength in e-commerce, AFH recovery led by Europe and US, execution focus







Sustained At Home habits

Focus on execution coupled with targetted reinvestments Translating in market share gains on strategic battles

Accelerated brand support on key growth platforms





+10bps YTD +70bps QTD



+70bps YTD in Europe



+50bps YTD in France +110bps YTD in Germany



+30bps YTD +70bps QTD



+30bps YTD in France +30bps YTD in Spain



+30bps YTD Worldwide +90bps YTD in the UK



+10bps in France +50bps in the UK



+20bps YTD

Market share evolution vs LY



Clear productivity step-up and selective pricing To manage exceptional commodity inflation

↓ ~ **420**bps inflation

incl. milk and ingredients, plastic, packaging and transportation

1 ~ 320bps productivity

SKU rationalization

Design to superior value



Local First organizational backbone Progressing according to plan

A growth enabler

Cross-category backbone

Reinvestments

Progress according to plan

€700m

gross savings by 2023 confirmed

Clear priorities for the second half of the year Focused on delivering on Company guidance

Local First project

Cross-category leaner organization

People engagement

Support, inclusiveness, energy

Quality of execution

Topline and efficiency

Brand support & reinvestment

Focused on strategic battles







Financial Review

Juergen Esser

Chief Financial Officer





Font Vella

probiotiques

:8:





Actim^el

POWER

Sales bridge

+6.6% like for like sales growth in Q2





(1) Includes IAS 29 and contribution to growth from hyperinflation geographies

Specialized Nutrition Adult Nutrition driving growth, contrasted dynamics in Infant Nutrition





Q2 developments

High single-digit growth in Adult Nutrition

Driven by both Oral and Tube feeding platforms

Contrasted dynamics of Infant Nutrition

- High single-digit growth in Europe thanks to softer basis of comparison
- Polarized performance in China:
 - Slightly positive for Domestic labels, against a high base of comp
 - Very strong growth of International labels in e-commerce platforms
 - _o -45% to -60% decline in cross-border indirect channels in line with H2 20
 - Aptamil market share continued to be resilient
- Another quarter of solid growth in platforms in Rest of the World

Like-for-like sales growth excluding hyperinflation countries

Essential Dairy & Plant-based All geographies contributing to growth



H1 2021 key figures			
Sales	€6.4bn		
Like-for-like change	+3.2%		
Volume / Value	+1.3% / +1.9%		
Recurring operating margin	9.1%		
Change	+5 bps		

Q2 developments

6th quarter of double-digit growth in Plant-based Solid growth in Essential Dairy led by Probiotics and Protein segments

Sustained solid growth in Europe and North America

- Europe growth led by Plant-based, Probiotics and Protein platforms: Alpro,
 Actimel and YoPro all growing double-digit and gaining share
- Noram Essential Dairy performance led by broad-based growth across the Yogurt segment, with share gains led by Oikos, Two Good and Activia
- Solid growth in Plant-based Noram led by the Yogurt and Creamers segments

Rest of the world: strong growth

- Soft quarter in CIS in a challenging macro and sanitary environment
- Favorable basis of comparison in Latam and Africa while restrictions remain

Like-for-like sales growth excluding hyperinflation countries





Progressive recovery in volumes; positive country and product mix



Q2 developments

Growth led by Small formats

Water and Beverage categories equally contributing to growth

Steep double-digit growth in Europe led by France, Germany and the UK

- Progressive and sequential recovery of mobility during the quarter
- Continued share gains across geographies by Volvic and evian

H1 2021 key figures

Sales €1.9bn

Like-for-like change +4.5%

Volume / Value -2.3% / +6.8%

Recurring operating margin 8.5%

Change +219 bps

3rd consecutive positive quarter for Mizone, up low double-digit

Steep double-digit growth in Indonesia and Latam

- Driven by momentary mobility improvement and Q2 2020 low base
- Latest wave of restrictions negatively impacting mobility

Like-for-like sales growth excluding hyperinflation countries

H1 2021 recurring operating margin


Price and strong productivity partially offset Volume, Mix and Inflation headwinds



DANONE ONE PLANET. ONE HEALTH (1) Including IAS 29

EPS bridge

Reported EPS +5.1%, Recurring EPS -9.3%



Non-recurring net income

Impacted by Transformation and Portfolio management

H1 Non-recurring operating margin

- €700m

mainly Local First & Operations transformation

Mengniu disposal

Gross proceeds

c. €1.6bn

Mengniu book value

c. €850m[®]

Capital allocation

Balancing investments, balance sheet management and shareholder returns

Free cash flow

€1.0bn

8.5% conversion rate (+90 bps vs LY)

-2.9%

WK/Net Sales (~50 bps improvement vs LY) **Net Debt**

€11.1bn

Net debt

€1.0bn

successful bond emission in June 2021 at 0% coupon **Shareholder returns**

Up to

€800m

share buyback program in H2 2021

Continued progress on our sustainability agenda Among which strong industry-leading recognitions

The healthiest portfolio

#1 on product profile in ATNI's ranking

88% of volumes sold Nutri-Score A or B (or equivalent) Leading on environment

Triple certification of Poços de Caldas

carbon neutrality, water circularity & zero-waste to landfill

Pioneering societal impact

Livelihoods
Carbon
Fund #3

supporting rural communities and preserving natural ecosystems







85/100 in S&P ESG Evaluation

"Among the most prepared companies to take advantage of long-term trends in the food and beverage industry"

2021 Outlook

H2 priorities

Quality of execution

People engagement

Brand support & reinvestment

Local First project

Macro context

Covid-19 evolution and pace of recovery

High inflation environment

2021 guidance confirmed

Back to profitable growth in H2

FY recurring operating margin expected broadly in line with last year








H1 2021

Appendix







Q2 2021 sales by reporting entity – breakdown volume/value

By reporting entity

By geographical area









Q2 2021 sales by reporting entity and by geographical area

	Essential Dairy & Plant-based	Specialized Nutrition	Waters	Company
Europe and Noram Sales LFL growth	€2,285m	€723m	€503m	€3,510m
	+4.0%	+6.1%	+19.8%	+6.4%
Rest of the world Sales LFL growth	€968m	€1,070m	€622m	€2,661m
	+6.9%	+0.7%	+19.3%	+6.9%
Company Sales LFL growth	€3,254m +4.8%	€1,793m +2.8%	€1,125m +19.5%	€6,171m +6.6%

Q2 & H1 2021 impact of currencies & scope

Q2 2021	Essential Dairy & Plant-based	Specialized Nutrition	Waters	Total
Reported sales growth	+0.5%	+0.1%	+21.6%	+3.6%
Organic contribution from hyperinflation countries	+0.5%	+0.5%	+1.0%	+0.5%
Currency and others(1)	-5.4%	-3.4%	-1.1%	-4.3%
IAS 29 impact	+0.1%	+0.1%	-0.0%	+0.1%
Scope	+0.5%	+0.1%	+2.3%	+0.7%
Like-for-like sales growth	+4.8%	+2.8%	+19.5%	+6.6%

H1 2021	Essential Dairy & Plant-based	Specialized Nutrition	Waters	Total
Reported sales growth	-2.9%	-6.0%	+3.5%	-2.9%
Organic contribution from hyperinflation countries	+0.4%	+0.4%	+0.7%	+0.4%
Currency and others ⁽¹⁾	-7.0%	-4.1%	-4.2%	-5.7%
IAS 29 impact	+0.2%	+0.2%	+0.2%	+0.2%
Scope	+0.2%	+0.1%	+2.3%	+0.5%
Like-for-like sales growth	+3.2%	-2.6%	+4.5%	+1.6%

(1) Excluding IAS29 impact




Changes in exchange rates

	% total H1 2021	H1 21 vs H1 20 (avg)	Q2 21 vs Q2 20 (avg)
United States Dollar	21.7%	-8.5%	-8.6%
Chinese Renminbi	7.4%	-0.5%	0.0%
Indonesian Rupiah	5.7%	-7.0%	-5.5%
Russian Ruble	5.4%	-14.3%	-10.7%
British Pound	5.3%	+0.7%	+2.9%
Mexican Peso	4.0%	-2.0%	+8.7%
Polish Zloty	2.6%	-2.8%	-0.4%
Srazilian Real	2.4%	-16.6%	-5.1%
Hong Kong Dollar	2.0%	-8.6%	-8.8%
Argentine Peso	1.6%	-35.6%	-33.3%
Japanese Yen	1.4%	-8.1%	-9.9%
Australian Dollar	1.1%	+7.4%	+6.9%
C* Turkish Lira	1.8%	-24.9%	-24.3%

Recurring operating margin

Recurring operating profit	H1 2020		H1 2021		Change	
(€m) and margin (%)	€m	Margin (%)	€m	Margin (%)	Reported	Like-for-like
Essential Dairy & Plant-based	598	9.1%	584	9.1%	+5 bps	-4 bps
Specialized Nutrition	987	26.4%	804	22.9%	-351 bps	-293 bps
Waters	117	6.3%	163	8.5%	+219 bps	+185 bps
Europe & Noram	880	12.9%	898	13.2%	+34 bps	+34 bps
Rest of the world	822	15.3%	653	12.9%	-239 bps	-245 bps
Total	1,702	14.0%	1,551	13.1%	-86 bps	-83 bps

Balance sheet



(1) Excluding assets included in net debt (2) Net of cash, cash equivalents, marketable securities, other short-term investments and financial instrument asset